Should We Continue or Discontinue Inflammatory Bowel Disease Medication in Patients With Coronavirus Disease 2019?

Hayashi, Yuki; Nakase, Hiroshi; Hisamatsu, Tadakazu

Hayashi, Yuki; Nakase, Hiroshi; Hisamatsu, Tadakazu.

Hayashi Y; Department of Gastroenterology and Hepatology, Sapporo Medical University of Medicine, Sapporo, Japan.
Nakase H; Department of Gastroenterology and Hepatology, Sapporo Medical University of Medicine, Sapporo, Japan.
Hisamatsu T; Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Tokyo, Japan.

Gastroenterology ; 163(1): 338-339, 2022 07.

Article in English | MEDLINE | ID: covidwho-1908322

Subject(s)

COVID-19; Inflammatory Bowel Diseases; Chronic Disease; Humans; Inflammatory Bowel Diseases/drug therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Limits: Humans Language: English Journal: Gastroenterology Year: 2022 Document Type: Article Affiliation country: J.gastro.2022.03.008

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google